Cancer Research · global
Turning Macrophages in Ascites Against Cancer: mRNA Nanoparticles Serve as Both Carrier and Drug
A lipid nanoparticle delivers CAR instructions into macrophages while promoting degradation of the immunosuppressive receptor TREM2. Patient samples and mouse experiments show anticancer signals, but key questions remain before efficacy in humans can be established.
When cancer spreads to the peritoneum and causes malignant ascites, treatment must contend not only with cancer cells but also with an environment that hinders immune responses. A new study attempts to change this situation by reprogramming macrophages in ascites that might otherwise support tumors, turning them into helpers that recognize cancer cells on site.
The study, published on November 6 in *Nature Materials*, used lipid nanoparticles carrying messenger RNA (mRNA) to enable macrophages to produce chimeric antigen receptors (CARs). These receptors act as added recognition devices, designed in this study to target cancer cells bearing the Claudin18.2 marker. The modified cells become CAR macrophages.
The design also addresses another obstacle. The study targeted tumor-associated macrophages bearing the TREM2 receptor and used the nanoparticles’ lipid composition to promote cellular internalization of TREM2 and its delivery to degradation pathways. In other words, beyond delivering genetic instructions, the particles also help weaken the immunosuppressive state of macrophages, creating conditions for anticancer activity.
In an accompanying commentary published the same day, Irene de Lázaro identified this dual function as a central feature of the study: the carrier itself also has therapeutic activity. She noted that the lipid components promote degradation of the immunosuppressive receptor, while the mRNA enables cells to acquire CAR function directly within malignant ascites associated with gastrointestinal cancers. Together, these effects alter the local immune environment.
The evidence comes from patient-derived samples and animal models. In ex vivo experiments using patient ascites, the researchers observed a weakening of the immunosuppressive state of macrophages, increased T-cell activation, and a reduction in tumor cells bearing the Claudin18.2 marker. Mouse experiments showed that combining this strategy with PD-1 blockade could inhibit tumor growth and prolong survival.
These results do not yet establish patient benefit. The patient samples were treated outside the body, while the evidence of improved survival came from mice. These findings support biological activity and a rationale for further development, respectively, but remain insufficient to demonstrate efficacy in humans. The effective dose, duration of action, and safety of repeated dosing all require clarification through further research.
The significance of this work lies in bringing cell reprogramming and modification of the immune environment into a single material design. To move toward clinical use, researchers must also demonstrate that the nanoparticles can reliably reach their target cells in the human body and weaken tumor-associated immunosuppression while avoiding damage to normal tissues. The current findings offer an experimentally supported development path, but not yet a treatment available to patients.